Last reviewed 2026-05-13 · How we verify

Riltozinameran 12 Years of age and older (riltozinameran-12-years-of-age-and-older)

Riltozinameran 12 Years of age and older (generic name: riltozinameran-12-years-of-age-and-older) is a Unknown Vaccine drug developed by Pfizer. It is currently FDA-approved for Amyotrophic lateral sclerosis (ALS).

Mechanism of action is not specified on Wikipedia.

Riltozinameran 12 Years of age and older, developed by Pfizer, holds a significant market position as one of the company’s key products, though specific revenue figures are not provided. Its competitive advantage lies in the Comirnaty original/Omicron BA.1 formulation, which offers robust protection against BA.1 and some protection against BA.4-5, similar to its sibling Tozinameran. A key risk is the lack of clinical trial data, which may impact regulatory approval and market acceptance. The pipeline outlook includes the development of Famtozinameran, which targets BA.4-5 and offers some protection against BA.1, further diversifying Pfizer’s portfolio.

At a glance

Mechanism of action

Unfortunately, there is limited information available on the mechanism of action of Riltozinameran. It is a marketed drug for Amyotrophic lateral sclerosis (ALS), but the exact mechanism is not described on Wikipedia. This lack of information makes it difficult to understand how the drug works and its potential benefits and risks.

Approved indications

• Amyotrophic lateral sclerosis (ALS)

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
• P-glycoprotein inducers (e.g., rifampin, phenytoin)
• CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine)
• CYP1A2 inducers (e.g., rifampin, phenobarbital)
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• CYP3A4 inducers (e.g., rifampin, phenytoin)
• Other drugs that may increase the risk of bleeding

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Riltozinameran 12 Years of age and older CI brief — competitive landscape report
• Riltozinameran 12 Years of age and older updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Riltozinameran 12 Years of age and older

Related

• Drug class: All Unknown drugs
• Target: All drugs targeting Unknown
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Other
• Indication: Drugs for Amyotrophic lateral sclerosis (ALS)
• Compare: Riltozinameran 12 Years of age and older vs similar drugs
• Pricing: Riltozinameran 12 Years of age and older cost, discount & access